Mesa Laboratories, Inc. (MLAB)
Nasdaq · Technology · Scientific & Technical Instruments
$142.23+7.30%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $796M
- P/E (trailing)
- 156.3
- Forward P/E
- 13.8
- Dividend yield
- 0.5%
- 52-week range
- $66.56 – $143.43
- 52-week change
- +94.35%
- EPS (trailing)
- $0.91
- Analyst rating
- 2.0 Buy
- Next earnings
- Nov 5, 2026
Fiscal year to Mar 2026
- Revenue
- $249M (+3.38%)
- Net income
- $6.7M
- Operating margin
- 7.4%
- Diluted EPS
- $1.21
- Free cash flow
- $39.6M
From the company’s annual report on SEC EDGAR.
About Mesa Laboratories, Inc.
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research.
Headquarters: Lakewood, United States · 717 employees · mesalabs.com